|
|
 |
|
Total Number of Holdings (excluding cash): 49
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
58,416 |
$71,306,074.56 |
7.64% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
265,645 |
$69,917,764.00 |
7.49% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
248,214 |
$66,206,120.22 |
7.09% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
497,852 |
$65,626,850.64 |
7.03% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
988,622 |
$62,876,359.20 |
6.74% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
2,064,857 |
$36,878,346.02 |
3.95% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
160,617 |
$33,024,461.37 |
3.54% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Drug Retailers |
134,692 |
$31,317,236.92 |
3.36% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
79,588 |
$31,286,042.80 |
3.35% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
62,164 |
$30,484,603.96 |
3.27% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
1,114,859 |
$28,150,189.75 |
3.02% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
206,781 |
$27,774,823.92 |
2.98% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
39,556 |
$27,498,540.08 |
2.95% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
190,768 |
$24,786,486.24 |
2.66% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
93,267 |
$23,962,157.64 |
2.57% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
45,674 |
$23,916,276.62 |
2.56% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
102,198 |
$19,722,170.04 |
2.11% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
235,036 |
$18,217,640.36 |
1.95% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
286,840 |
$16,209,328.40 |
1.74% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
59,346 |
$14,268,558.78 |
1.53% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
24,028 |
$13,719,267.16 |
1.47% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
73,471 |
$13,432,702.93 |
1.44% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
233,630 |
$11,798,315.00 |
1.26% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
139,873 |
$11,671,702.50 |
1.25% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
152,129 |
$11,469,005.31 |
1.23% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
176,164 |
$10,934,499.48 |
1.17% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
98,448 |
$9,840,862.08 |
1.05% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
184,148 |
$8,664,163.40 |
0.93% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
90,428 |
$8,007,399.40 |
0.86% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
142,247 |
$7,953,029.77 |
0.85% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
304,745 |
$7,777,092.40 |
0.83% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
140,834 |
$7,727,561.58 |
0.83% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
362,207 |
$6,795,003.32 |
0.73% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
45,212 |
$6,493,347.44 |
0.70% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
46,151 |
$6,315,302.84 |
0.68% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
72,996 |
$6,261,596.88 |
0.67% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
21,206 |
$6,282,913.68 |
0.67% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
15,533 |
$5,657,584.59 |
0.61% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
208,180 |
$5,631,269.00 |
0.60% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
46,145 |
$5,178,853.35 |
0.55% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
46,616 |
$4,948,754.56 |
0.53% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
146,483 |
$4,956,984.72 |
0.53% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
172,843 |
$4,495,646.43 |
0.48% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
157,307 |
$4,470,664.94 |
0.48% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
79,129 |
$4,415,793.85 |
0.47% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
77,258 |
$3,687,524.34 |
0.40% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
12,718 |
$3,667,998.38 |
0.39% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
56,055 |
$3,304,442.25 |
0.35% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
52,279 |
$2,891,028.70 |
0.31% |
| US Dollar |
$USD |
|
Other |
1,499,703 |
$1,499,703.33 |
0.16% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|